YOUNG HIGH RISK PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA INCLUDING BCL‐2/MYC DOUBLE HIT LYMPHOMAS BENEFIT FROM DOSE‐DENSE IMMUNOCHEMOTHERAPY WITH EARLY CNS PROPHYLAXIS. (12th June 2019)